Tissue Repair Ltd (TRP) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 63.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: 372.71%
• EPS Growth: -35.61%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 60,464,844
• 10 Day Avg. Volume: 50,576
• 30 Day Avg. Volume: 63,091
• PEG Ratio: 0.36
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Tissue Repair Ltd faces significant challenges, including negative net income and cash flow issues, despite strong revenue growth and a solid balance sheet. The bearish technical indicators and negative valuation metrics further impact the stock's outlook. Improvement in profitability and cash management are essential for future stability and growth.

Tissue Repair Ltd Business Overview & Revenue Model

Company Description

Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.

How the Company Makes Money

Tissue Repair Ltd generates revenue primarily through the sale of its proprietary therapeutic products to hospitals, clinics, and healthcare providers. These products are marketed and distributed both directly and through strategic partnerships with pharmaceutical companies and medical device distributors. TRP also earns income through licensing agreements, where it grants rights to other companies to use its patented technologies in exchange for royalties or upfront payments. Additionally, TRP may receive funding through research grants and collaborations with academic institutions or government agencies, which support the development of new therapies and expand its product pipeline.

Tissue Repair Ltd Financial Statement Overview

Summary

Tissue Repair Ltd shows strong revenue growth but struggles with negative net income and cash flow issues. The balance sheet is strong due to no debt and robust equity, but the company's inability to generate returns and negative cash flow limits financial stability.

Income Statement

Tissue Repair Ltd has shown significant revenue growth from 2023 to 2024, indicating potential market acceptance. However, the company continues to suffer from negative net income and EBIT, which suggests ongoing operational challenges with profitability. The gross profit margin is high, but net profit margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a low-risk balance sheet. The equity ratio is robust, highlighting a solid capital structure. However, the company's ability to generate returns on equity is hampered by consistent net losses.

Cash Flow

Operating cash flow remains negative, indicating cash burn issues. Free cash flow has deteriorated over the year, reflecting increased operational cash outflows. The lack of financing cash flow suggests limited external funding, which could pose liquidity risks if negative cash flows continue.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
2.39M	152.24K	3.08K	171.92K	152.64K	156.00
	Gross Profit
2.38M	152.24K	428.00	170.21K	152.64K	156.00
	EBIT
-5.54M	-6.52M	-5.74M	-6.84M	-639.70K	-448.72K
	EBITDA
-5.53M	-6.51M	-5.14M	-7.01M	-189.44K	-52.19K
	Net Income Common Stockholders
-4.44M	-4.14M	-4.17M	-6.84M	-915.23K	-352.21K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
14.43M	16.44M	21.40M	25.46M	27.11M	1.15M
	Total Assets
16.71M	19.39M	22.38M	25.90M	27.61M	1.33M
	Total Debt
0.00	0.00	0.00	0.00	7.50M	0.00
	Net Debt
-14.43M	-16.44M	-21.40M	-25.46M	-19.61M	-1.15M
	Total Liabilities
1.13M	1.35M	497.35K	559.64K	536.00K	329.11K
	Stockholders Equity
15.58M	18.04M	21.88M	25.34M	27.07M	999.90K
Cash Flow		Free Cash Flow
-5.39M	-4.95M	-4.26M	-3.97M	-852.89K	-649.98K
	Operating Cash Flow
-5.38M	-4.95M	-4.26M	-3.97M	-852.89K	-649.98K
	Investing Cash Flow
-10.04K	-3.35K	-2.24K	-3.92K	5.00K	0.00
	Financing Cash Flow
0.00	0.00	0.00	21.36M	7.46M	1.20M

Tissue Repair Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.24, and below the 200-day MA of 0.30, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 11.83 is Positive, neither overbought nor oversold. The STOCH value of 37.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRP.

Tissue Repair Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
CYC	45 Neutral	AU$128.36M	―	-35.20%	―	4.68%	-155.42%
TRP	42 Neutral		―	-25.11%	―	372.71%	-35.61%
POL	39 Underperform	AU$202.99M	―	-39.56%	―	―	51.63%
RCE	37 Underperform	AU$82.51M	―		―	―	-33.01%

Tissue Repair Ltd Corporate Events

Tissue Repair Ltd Advances Phase 3 Trials Amid Regulatory Challenges

Tissue Repair Ltd has made significant progress in the March 2025 quarter, particularly with its TR987® drug, which is in Phase 3 trials for chronic wounds. Despite regulatory challenges in the US wound care market, the company is advancing its trials and expects to increase patient enrollment. Additionally, Tissue Repair is working on expanding the manufacturing capabilities for its TR Pro+® product, which saw record sales in March, and is pursuing distribution arrangements to enhance its market reach. Financially, the company reported a cash position of $12.6 million as of March 31, 2025, with ongoing investments in clinical trials and product development.

Tissue Repair Ltd Appoints New CFO to Strengthen Financial Leadership

Tissue Repair Limited has appointed Mr. Dion Cohen as its new Chief Financial Officer, effective March 31, 2025, replacing Mr. Cameron Peter Jones. This strategic move marks a shift from outsourced CFO functions to having an in-house CFO, which is expected to enhance collaboration with the CEO and clinical teams, particularly in executing the Phase III trial for TR-987 and advancing the TR Pro+ product line.

Tissue Repair Ltd Sees Revenue Surge Amid Rising Losses

Tissue Repair Ltd reported a significant increase in revenues by 98.2% to $900,898 for the half-year ended December 2024, despite a rise in losses by 13.5% to $2,560,868. The company did not declare any dividends during this period, and the net tangible assets per ordinary security decreased from 29.83 cents to 25.77 cents, indicating a challenging financial landscape despite revenue growth.